Small-for-Size Syndrome After Living Donor Liver Transplantation by Yuzo Umeda
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Small-for-Size Syndrome After  
Living Donor Liver Transplantation  
Yuzo Umeda, Takahito Yagi, Hiroshi Sadamori and Toshiyoshi Fujiwara 
Department of Gastroenterological Surgery, 
Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences 
Japan 
1. Introduction 
Patients scheduled for liver transplantation frequently have portal hypertension and 
consequently they are likely to have a high portal blood flow in the transplanted graft. 
When the graft volume is small in adult living donor liver transplantation with partial liver 
transplantation, various problems that may affect the prognosis often occur because the 
partial graft cannot sustain excessive portal blood perfusion. It is widely known that liver 
transplant recipients can potentially develop a specific syndrome known as “small-for-size 
syndrome”, when a small for size graft causes size mismatch in the presence of portal 
hypertension. The small-for-size syndrome can result in large-volume ascites, 
hyperbilirubinemia, and coagulopathy. The pathologic mechanism of small-for-size 
syndrome includes graft failure caused by excessive and destructive portal inflow into the 
small for size graft. The small-for-size syndrome is widely recognized by transplant surgeon 
as one of the important post-transplant events. Thus, sufficient graft volume is one of the 
important determinants of successful transplant and clinically satisfactory outcome. 
Particularly in the case of living donor liver transplantation, there is the added problem of 
insufficient donor pool and donor safety, but it is essential to maintain graft function under 
the given circumstances. The decision on the type of liver graft depends on various factors, 
such as recipients’ status and donor safety: a small for size graft tends to be selected due to 
problems related to donor selection and to ensure the safety of the donor. In this regard, 
many centers stipulate the absolute lack of various pre-transplant risk factors and a minimal 
graft size in order to prevent the development of this syndrome and good outcome.  
2. Pathophysiological mechanisms of small-for-size syndrome 
Small-for-size syndrome can occur in the special situation of partial liver graft 
transplantation, especially in adult living donor liver transplantation, with resultant size 
mismatching between graft size and recipient hepato-portal circulation. Once the partial 
liver volume graft is subjected to excessive portal inflow, portal hyperperfusion results in 
the development of the small-for-size syndrome. The basic pathophysiology in this 
syndrome relates to graft injury after transplantation, which is caused by graft size 
mismatch and portal hypertension, followed by the appearance of various clinical 
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abnormalities such as excessive ascites, hyperbilirubinemia, coagulopathy, encephalopathy, 
and renal dysfunction. Transplant recipients develop symptoms related to the above 
abnormalities after transplantation and post-transplant prognosis is reported to be less than 
ideal.  
To understand the pathophysiological mechanism of the small-for-size syndrome, several 
studies examined post-transplant biopsies. These studies reported histopathological 
evidence of mechanical injury and graft failure caused by destructive portal hyperperfusion. 
The main histopathological findings are: (1) Portal vein and periportal sinusoidal 
endothelial denudation and focal hemorrhage into the portal tract connective tissue; and (2) 
poor arterial flow and vasospasm, resulting in ischemic cholangitis and parenchymal infarct. 
Furthermore, electron microscopic examination showed sinusoidal congestion, excessive 
swelling of the mitochondria in hepatocytes, irregular large gaps of sinusoidal lining cells, 
and collapse of the space of Disse. These findings are considered to represent progressive 
damage of the graft resulting from microcirculatory failure due to irreversible endothelial 
injury after reperfusion. On the other hand, other studies examined the molecular basis of 
graft damage by analyzing intragraft gene expression. The results of these studies provided 
evidence for sinusoidal damage. Cases of small-for-size syndrome and associated graft 
dysfunction due to portal hyperperfusion, showed intragraft upregulation of endothelin-1 
and down regulation of heme-oxigenase-1 and heat shock protein-70. Others showed low 
portal venous plasma nitric oxide levels. In addition, experimental studies using animal 
models of the small-for-size syndrome showed intragraft over-expression of endothelin-1, 
early growth response -1 (Egr-1) and endotherin-1A receptor and significant changes in 
intragraft mRNA levels as well as plasma levels of inflammatory cytokines (interleukin [IL]-
6, IL-15, tumor necrosis factor [TNF]-alpha). Furthermore, the small for size isografts and 
allografts, with volumes measuring 50% or 30% of the liver graft volume, demonstrated 
higher expression levels of vascular endothelial growth factor (VEGF) and fetal liver kinase 
(Flk)-1 than the whole isograft and allograft.  In addition, Flk-1-positive activated 
macrophages were also detected in small for size isografts and allografts, which were 
probably induced by VEGF. In this regard, the expression of VEGF and its interaction with 
Flk-1 could mediate the inflammatory response, early activation of macrophages. Thus, the 
above changes in the small for size graft injury likely play important roles in the accelerated 
acute rejection process of the small for size allograft. 
Previous studies indicated that liver regeneration begins in the early period after partial 
liver transplantation. Although the detailed mechanism remains unknown at present, the 
high portal flow rate and high portal pressure are considered important triggers of liver 
regeneration. In partial liver transplantation, a high level of liver regeneration is observed 
when the graft size is small, or when portal pressure is high in cirrhotic patients. On the 
other hand, liver tissue damage and ischemic reperfusion injury caused by high portal 
pressure in small-for-size syndrome result in serious interference with the process of liver 
regeneration. Interestingly, IL-6 and TNF-alpha play key roles in liver regeneration, though 
they are also considered to represent markers of acute-phase tissue damage. Local activation 
and excessive production of these cytokines is associated with poor liver regeneration, since 
they can act as negative regulators of cell proliferation. In fact, TNF-alpha could trigger the 
cell death pathway after binding to the TNF-receptor. Thus, although the role of these 
cytokines remains controversial, they are considered to function as inflammatory cytokines, 
rather than as liver regenerative factors, in patients with small-for-size syndrome. 
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Furthermore, accumulation of oxygen free radicals in the graft could possibly contribute to 
graft dysfunction. 
3. Treatment strategy for small-for-size syndrome 
The most important step is prevention of small-for-size syndrome through perioperative 
treatment strategies that include approaches aimed at reducing excessive portal inflow as 
the major cause of small-for-size syndrome, and lowering the graft perfusion pressure. 
Furthermore, efforts should be made to prevent hepatic venous congestion due to 
insufficient vascular orifices or mechanical stenosis and kinking.  
An important factor in determining portal inflow volume and pressure is the blood 
perfusion level in the spleen, thus highlighting the benefits of splenectomy and ligation of 
the splenic artery. However, patients with end-stage hepatic failure exhibit a 
hyperdynamic state of splanchnic blood flow, compared with normal state, and are at 
increased risk of hemorrhage associated with seriously invasive surgical procedures. Thus, 
careful attention should be paid to the expansion of the dissection area during surgery, 
especially in patients with collateral circulation around the splenic artery, such as gastric 
coronary vein and spleno-renal shunt. However, the development of new surgical 
technique and advances in medical devices have allowed a reduction in blood loss during 
surgical dissection procedures and splenectomy. Although the invasiveness of surgical 
procedure such as splenectomy and splenic artery ligation could be diminished further, 
adverse events such as increased susceptibility to infection caused by low immunity and 
portal vein thrombosis, may occur after splenectomy. Thus, patients should be carefully 
selected for splenectomy and splenic artery ligation. 
Portosystemic shunt is currently considered an efficacious procedure in the treatment of 
portal hypertension. Especially adequate portosystemic shunt, which achieves favorable 
portal decompression to below 15 mmHg, could dramatically improve the post-transplant 
prognosis of patients with small for size graft. The procedure has allowed lowering the cut-
off value for graft weight-to-recipient body weight ratio from 0.8% to 0.6%. This procedure 
is anticipated to become the main strategy in the future to prevent the development of the 
small-for-size syndrome. However, the separation of the graft portal route, as seen in 
portosystemic shunt, may result in portal steal to the extrahepatic route, which sometimes 
leads to fatal events especially in cases with decreased graft portal vascular compliance, 
such as the case of steatotic liver graft or accute cellular rejection. Based on this potential 
complication, some centers have adopted certain precautionary measures against such 
complications using modifications of the shunt closing technique. 
The recently introduced approach of splenic artery embolization could be an effective 
procedure for portal decompression instead of the conventional treatment. Splenic artery 
embolization is described by some investigators as a rescue treatment for post-transplant 
small-for-size syndrome. In this regard, we previously reported that preoperative portal 
decompression by splenic artery embolization efficaciously reduced blood loss during 
operation and shortened the operating time, and that it contributed to favorable prognosis 
without serious complications related to the procedure itself. In our institution, preoperative 
embolization is selected for patients considered at risk of development of shunt in the  
peri-celiac trunk. The risk assessment is based on preoperative radiography showing 
possible problems with safety of splenic artery ligation. In each patient scheduled  
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for preoperative splenic artery embolization, abdominal angiography was performed 12 to 
18 hours before transplantation. As a rule, a metallic coil was placed in the area adjacent to 
the root of the splenic artery and proximal to the bifurcation of the major pancreatic artery, 
to produce total embolization of the splenic artery trunk (Figure 1). Evaluation of post-
transplantation graft hemodynamics by Doppler ultrasonography showed a significant 
reduction in the level of graft portal perfusion following splenic artery ligation and splenic 
artery embolization in the portal modulation group, compared with the non-portal 
modulation group (Figure 2). In the portal modulation group, the efficacy of portal 
decompression following splenic artery embolization was equivalent to that after splenic 
artery ligation. Furthermore, hepatic arterial flow was significantly higher during the 
postoperative phase in the portal modulation group, reflecting arterial flow shift from the 
spleen to the hepatic artery or hepatic arterial buffer response (Figure. 1). 
 
Fig. 1. Preoperative splenic artery embolization as a prophylactic procedure for the 
prevention of small-for-size syndrome. Splenic artery was totally embolized adjacent to the 
root of celiac artery, 12-18 hours before liver transplantation. Splenic artery embolization 
reduced portal flow and increased hepatic arterial flow. Preoperative portal decompression 
also decreased blood loss and shortened operative time 
As a result, such change in arterial blood flow could also contribute to the prevention of 
splenic artery steal syndrome, which causes poor arterial blood supply. Based on this 
procedure, none of the patients developed portal vein thrombosis or septicemia, which are 
sometimes observed after splenectomy. 
Another issue related to liver transplantation is the post-transplant course. In this regard, 
high level liver regeneration is observed when the graft size is small, or when portal 
pressure is high in cirrhotic patients. Importantly, high serum IL-6 concentrations are 
considered to reflect high hemodynamic shear stress, which could lead to regenerative 
signaling pathway. However, in patients with extra small for size graft, regeneration of the 
graft liver does not occur sometimes, and liver tissue damage and ischemic reperfusion 
injury could result in increased release of inflammatory cytokines, such as IL-6 and TNF-
alpha, which lead to poor liver regeneration, i.e., these cytokines act as negative regulators 
of cell proliferation. Thus, although the role of these cytokines remains controversial, they 
are considered to function as inflammatory cytokines, rather than as liver regenerative 
factors, in patients with small-for-size syndrome, and thus, are considered as markers of 
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graft injury. The postoperative outcome depends on the extent of graft injury immediately 
after the transplantation and portal decompression can protect the liver graft from 
destructive portal hyperperfusion and reduce the levels of these inflammatory cytokines. 
Our previous study reported that prophylactic splenic artery embolization and ligation 
decreased serum IL-6 and TNF-alpha after graft reperfusion and resulted in certain graft 
liver regeneration and favorable outcome. Based on these new findings, in terms of 
treatment strategy in small-for-size syndrome, prophylactic treatment would be favorable 
compared with rescue therapy.  
 
Fig. 2. Box-and-whisker plots of portal vein flow and hepatic artery flow in patients of the 
non-portal modulation (PM) and PM groups during postoperative days (POD) 1, 3, 5 and 7  
Any decision regarding the treatment strategy for small-for-size syndrome, flexible stance is 
often needed. Among the various approaches, either decision could be suitable depending 
on the individual patient. For example, the patient characteristics and institutional operative 
policies could influence the final decision. While portosystemic shunt is widely used for the 
prevention of small-for-size syndrome, there is no doubt that splenectomy and splenic 
artery ligation are also suitable and effective techniques to produce portal decompression. 
Furthermore, splenic artery embolization prior to transplantation could be an alternative 
effective treatment modality especially in patients with severe portal hypertension, and with 
established collateral circulation in the peri-celiac trunk, which makes it difficult to perform 
splenic artery ligation or splenectomy. In this regard, when sufficient portal decompression 
cannot be achieved through a single technique, a combination of two or more procedures 
should be applied. In essence, a proper portal decompression therapy can inhibit portal 
overperfusion injury and prevent small-for-size syndrome and also have beneficial effects 
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on liver generation as well as improvement of post-transplantation prognosis. In addition to 
the reduction in the mortality rate after the development of the technique of living donor 
liver transplantation, from medical and economic standpoints, the cost benefits of liver 
transplantation can be fully expected based on the reduced use of blood products, and 
shorter hospitalization through improvement of perioperative clinical condition.  
4. Prediction of small-for-size syndrome and hospital mortality  
Theoretically, small-for-size syndrome is expected in cases of small for size graft with high 
portal inflow. However, several studies have demonstrated that small-for-size syndrome 
does not necessarily occur even in such situations. In other words, the development of small 
for size syndrome and post-transplant graft function could not be predicted from the graft 
size only. We hypothesized that early graft function does not only depend on graft size, but 
also on portal hypertension, donor age and recipient status. To test our hypothesis, we 
determined the perioperative risk factors in small-for-size syndrome and post-transplant 
hospital death. In this regard, there are only a few studies that have dealt with the 
prediction of small-for-size syndrome in living donor liver transplantation.  
We analyzed retrospectively 200 consecutive adult patients who underwent living donor 
liver transplantation in our hospital during the period from August 1998 to January 2010. 
We used multivariate analysis of hospital deaths for this purpose and various clinical, 
pathological and surgical parameters, after employment of cut-off values for these 
parameters using ROC analysis. Patients were divided into two groups according to the 
treatment protocol for the prevention of small-for-size syndrome. The first 50 patients had 
not received any prophylactic portal decompression. There were significant differences in 
the clinical parameters based on the time trend between the groups with and without 
prophylactic portal decompression. Interestingly, an aggressive operative stance was 
identified in the late time group and this correlated with the recipient age, donor age, 
MELD, and graft volume. Meanwhile, there was a significant learning curve, which seemed 
to reflect the development of the operative procedure, including the cold ischemic time, 
blood loss, and operative time (Figure 3). In the first 50 cases, the in-hospital mortality rate 
and 1-year survival rates of patients with a graft weight (GW)/recipient body weight (RBW) 
rate less than 0.8% were 27.3% and 63.6%, respectively (Figure 4). Multivariate analysis 
identified a single factor, which was a graft weight (GW)/recipient body weight (RBW) rate 
less than 0.8%, as a significant determinant of post-transplant hospital death (Table 1). From 
the 51th patients onward, prophylactic portal decompression was used in 70 of the 150 
patients in order to prevent small-for-size syndrome. The prophylactic portal 
decompression consisted of splenic artery embolization in 50 patients, splenic arterial 
ligation in 14, splenectomy in 5, and portocaval shunt in 1 patient. After the introduction of 
the prophylactic portal decompression in the later 150 cases, the hospital mortality rate and 
1-year survival rate of patients with GW/RBW less than 0.8% were 7.2% and 86%, 
respectively. After the introduction of prophylactic portal decompression, post-transplant 
prognosis did not correlate with a cut-off value of 0.8% for the GW/RBW ratio (Figure 4). 
Multivariate analysis of post-transplant hospital mortality rate in the later 150 cases 
identified donor age more than 54 years and MELD score more than 23, but not the 
GW/RBW, as significant perioperative risk factors (Table 2). In other words, the minimum 
GW/RBW ratio could be safely lowered to 0.68% with adequate portal modulation. 
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Variables n Odds ratio P-Value 
Recipient factors     
Age ≥ 50 (vs < 50 years)  22 / 28 23.4 0.99 
MELD ≥ 20 (vs < 20)  2 / 48 6.29 0.23 
Disease     
Cholestatic disease vs PLC 22 / 19 0.34 0.21 
Acute liver failure vs PLC 9 / 19 1.39 - 
Donor factors    
Age ≥ 53 (vs < 53 years) 10 / 40 1.15 0.92 
Graft type (right lobe vs left lobe graft) 38 / 12 0.29 0.46 
GW/RBW < 0.8% (vs ≥ 0.8%)  12 / 38 8.44 0.02 
Treatment and Operative factors    
Blood loss ≥ 50 (vs < 50ml/kg) 39 / 11 3.59 0.99 
CIT ≥ 80 (vs < 80min) 16 / 34 1.16 0.91 
WIT ≥ 50 (vs < 50min) 14 / 36 1.92 0.40 
Operating time ≥10 (vs <10 hrs) 38 / 12 4.56 0.74 
Table 1. Logistic regression analysis of post-transplant hospital mortality (the first 50 cases). 
PLC, Post-necrotic Liver cirrhosis; MELD, Model for End-stage Liver Disease; GW/RBW, 
Graft weight to recipient body weight ratio; CIT, Cold ischemic time; WIT, Warm ischemic 
time 
 
Fig. 3. Box-and-whisker plots of clinical factors in the first 50 cases (right side) and the later 
150 cases (left side) 
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Fig. 4. Overall survival curves and hospital mortality before and after the introduction of 
portal modulation 
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Fig. 5. Correlation between graft size, MELD, and donor age in cases of small-for-size 
syndrome and hospital death 
To evaluate the impact of small for size graft on the outcome, we defined small-for-size 
syndrome as both prolonged functional cholestasis and intractable ascites. Prolonged 
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functional cholestasis was defined as total bilirubin >10 mg/dL at postoperative day 14, 
without any other cause of cholestasis. Intractable ascites was defined as daily production of 
ascites of more than one liter at postoperative day 14 or >500 mL at postoperative day 28. 
Production of ascites represented the daily volume of ascites estimated by discharge from 
the abdominal drain. According to this diagnostic criterion, small-for-size syndrome occurred 
in 21 of 200 cases (10.5%) and 5 cases had fatal outcome. Patients with the small-for-size 
syndrome consisted of 11 cases (22%) in the first 50 cases and 10 cases (6.7%) in the later 150 
cases, respectively. Furthermore, early hospital death was noted in 16 of 200 cases (8%). 
 
Fig. 6. Decision tree analysis of post-transplant hospital mortality (175 cases). MELD, model 
for end-stage liver disease; GRWR, graft weight to recipient body weight ratio; SAM, splenic 
artery embolization as portal modulation 
The occurrence of small-for-size syndrome and hospital death depends on the specific 
combination of graft size, donor age, and MELD. Even using large-size graft, the use of 
grafts with high MELD and from old-age donors tended to result in the development of 
small-for-size syndrome and hospital mortality (Figure 5). These results indicated that the 
use if sufficient graft volume does not prevent the development of small-for-size syndrome 
graft, and that the incidence of this syndrome depends on other risk factors, which affect the 
post-transplant prognosis. Concerning the prediction of small-for-size syndrome or post-
transplant prognosis, none of the analyses used could find significant risk factors. The 
decision tree analysis for hospital mortality indicated that the value of any one risk factor 
should affect the cut-off values of other risk factors (Figure 6). Thus, early graft function and 
hospital mortality are determined not only by graft size, but also by donor age and recipient 
status. Donor age and graft size should be matched to the recipient status when possible, 
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and when not possible, portal modulation should be considered. Splenic artery embolization 
could help reduce the morbidity and mortality rates, as well as increase the survival rates, 
and should be considered along with the other perioperative risk factors. 
Variable n 
Odds 
ratio 
P-Value 
Recipient factors    
Age ≥ 54 (vs < 54 years) 78 / 72 1.54 0.59 
MELD ≥ 23 (vs < 23) 24 / 126 3.66 0.001 
Disease    
Cholestatic disease vs PLC 21 / 115 0.61 0.73 
Acute liver failure vs PLC 14 / 115 1.39  
Donor factors    
Age ≥ 53 (vs < 53 years) 33 / 117 6.84 0.03 
Graft type (Right lobe vs Left lobe graft) 80 / 70 0.47 0.44 
GW/RBW < 0.68% (vs ≥ 0.68%) 26 / 124 1.41 0.72 
Treatment and Operative factor    
Portal modulation 70 / 80 0.61 0.54 
Blood loss ≥ 50 (vs < 50ml/kg) 101 / 49 1.90 0.61 
CIT ≥ 80 (vs < 80min) 35 / 115 1.91 0.40 
WIT ≥ 50 (vs < 50min) 42 / 108 1.87 0.74 
Operating time ≥ 10 (vs < 10hrs) 59 / 91 3.98 0.39 
Table 2. Logistic regression analysis of post-transplant hospital mortality (the later 150 cases). 
LC, post-necrotic liver cirrhosis; MELD, model for end-stage liver disease; GW/RBW, graft 
weight to recipient body weight ratio; CIT, cold ischemic time; WIT, warm ischemic time 
5. Conclusion 
Recently published clinical trials and basic research conducted by several groups have 
uncovered the mechanism of small-for-size syndrome, allowing the design and 
implementation of new treatment strategies. These advances have resulted in significant 
improvement in prognosis after living donor transplantation. Further improvement of liver 
transplantation and liver surgery techniques should result in better outcome of patients with 
small for size syndrome. 
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